Five Prime Therapeutics (FPRX) Misses Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to Five Prime Therapeutics (FPRX) Misses Q3 EPS by 21c

Five Prime Announces Third Quarter 2016 Results and Provides Business Update

November 3, 2016 4:06 PM EDT

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the third quarter ended September 30, 2016.

"We have continued to make progress on all of our clinical and preclinical programs during the quarter, said Lewis T. "Rusty" Williams, M.D., Ph.D., president and chief executive officer of Five Prime. "We achieved an important milestone by advancing into the Phase 1b portion of our clinical trial evaluating... More